Vesugen
Also called KED; Lys-Glu-Asp; Vezugen
A three-amino-acid bioregulator peptide studied for effects on blood-vessel lining cells. Research includes lab work and small human reports with notable inconsistencies; it does not establish circulation or anti-aging benefits.
Overview
What it is
A tripeptide of lysine, glutamic acid and aspartic acid.
How it works
In vascular cell cultures, it increased Ki-67, a marker of cell division, and computer modeling suggested an interaction with the gene that controls it. Another lab study reported changes in endothelin-1, connexin and SIRT1 in diseased vessel-lining cells.
What the research shows
A 2013 report on leg artery insufficiency described better blood-flow measures but lacked comparison details. A 2014 report has a title and abstract that describe different conditions. A 2015 aging report has a participant-count error and noted pro-oxidant activity and lower CD34-positive cell markers.
Studied for
- Vessel-lining cell growthlab
- Leg circulationsmall human reports
- Aging markerssmall report, mixed
Safety and regulatory status
Safety and side effects
No reliable side-effect profile or long-term safety data. The pro-oxidant finding argues against calling it a proven antioxidant. Talk to your clinician before combining with blood pressure or other heart medications.
Regulatory status
Not approved by the FDA for any use.
Mixing and dosing reference
Reference information only. Read before using this section.
Vesugen (Lys-Glu-Asp) (20 mg Vial) Dosage Protocol
- Vial
- 20 mg Vesugen (Lys-Glu-Asp)
- Add diluent
- 3 mL
- Concentration
- 6.67 mg/mL
- 1 unit (U-100)
- 66.67 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous).
- Typical range
- 500–2000 mcg once daily (gradual titration).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks.
Standard / Gradual Approach
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 500 mcg (0.5 mg) | 7.5 units (0.075 mL) |
| Week 2 | 1000 mcg (1.0 mg) | 15 units (0.15 mL) |
| Week 3 | 1500 mcg (1.5 mg) | 22.5 units (0.225 mL) |
| Weeks 4–8+ | 1500–2000 mcg (1.5–2.0 mg) | 22.5–30 units (0.225–0.30 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 500 mcg daily; increase by ~500 mcg weekly as tolerated.
- Target: 1500–2000 mcg daily by Weeks 3–8+.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
Important notes
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
Protocol source: PeptideDosages.com
Common questions
Does Vesugen improve circulation?
It has been studied for vascular effects, which is not the same as proven improvement.
Is it an antioxidant?
One report found pro-oxidant activity, so that claim is not supported.
How is it different from BPC-157?
They are unrelated peptides with separate research.
Related in Healthy Aging
Sources and further reading (5)
- Kozlov KL, et al. Vasoprotective peptide KED in atherosclerosis and restenosis. Adv Gerontol, 2016.
- Kitachov KV, et al. Vasoactive peptide in lower-limb chronic arterial insufficiency. Adv Gerontol, 2013.
- Khavinson VK, et al. Peptidergic regulation of vascular endothelial cell proliferation during aging. Adv Gerontol, 2014.
- Meshchaninov VN, et al. Synthetic peptides and aging in chronic polymorbidity. Adv Gerontol, 2015.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).